Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13063496 | 0.78 | XDH (0.33) | XDH | |
| SCHEMBL144243 | 0.74 | ADRB2 (0.43) | ADRB2XDHGAAMAPTCA1 | |
| SCHEMBL10119242 | 0.74 | MAPT (0.56) | ADRB2XDHGAAMAPTCA1 | |
| SCHEMBL29582221 | 0.74 | ADRB2 (0.43) | ADRB2XDHGAAMAPTCA1 | |
| SCHEMBL12145185 | 0.73 | MAOB (0.34) | MAPT | |
| SCHEMBL11436064 | 0.72 | TTR (0.50) | ADRB2XDHGAAMAPTCA1 | |
| SCHEMBL28213986 | 0.72 | GAA (0.37) | GAAMAPTCA1CA2CA3 | |
| SCHEMBL31392497 | 0.71 | ADRB2 (0.44) | ADRB2XDHGAAMAPTHTT | |
| SCHEMBL11040450 | 0.71 | ADRB2 (0.41) | ADRB2XDHGAAMAPTCA1 | |
| SCHEMBL29187435 | 0.70 | CA2 (0.64) | ADRB2CA1CA2CA3CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | RBP1, RBP4, VCAM1 | ADRB2 3090/4885XDH 1031/4885GAA 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.